Global Liposomal Products Market 2023-2027: Rising Incidence of Fungal Disorders to Drive $3 Billion Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Liposomal Products Market 2023-2027” report has been added to ResearchAndMarkets.com’s offering.
The liposomal products market is forecast to grow by $3,183.63 mn during 2022-2027, accelerating at a CAGR of 9.65% during the forecast period. Our report on the liposomal products market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising incidence of fungal disorders, the growing prevalence of cancer cases, and side effects associated with cancer treatment.
The publisher’s liposomal products market is segmented as below:
By Application
- Cancer
- Fungal infections
- Pain management
- Viral vaccines
- Photodynamic therapy
By Type
- Branded
- Generic
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the rising adoption of quality by design (QBD) over traditional processes as one of the prime reasons driving the liposomal products market growth during the next few years. Also, increase in strategic collaboration and rising popularity of liposomal products with enhancing circulation time of hydrophobic substances will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the liposomal products market covers the following areas:
- Liposomal products market sizing
- Liposomal products market forecast
- Liposomal products market industry analysis
The publisher’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liposomal products market vendors that include Acthera Therapeutics AG, Bausch Health Companies Inc., Baxter International Inc., Galen Ltd., GENFIT SA, Gilead Sciences Inc., Innocan Pharma Corp. Ltd., Johnson and Johnson Services Inc., Leadiant Biosciences Inc., Lipella Pharmaceuticals Inc., Liposoma B.V., Merrimack Pharmaceuticals Inc., Nanovex Biotechnologies SL, Pacira BioSciences Inc., Spectrum Pharmaceuticals Inc., Taiwan Liposome Co. Ltd., Takeda Pharmaceutical Co. Ltd., The Lubrizol Corp., Vascular Biosciences, and Viatris Inc. Also, the liposomal products market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. The publisher’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
A selection of companies mentioned in this report includes
- Acthera Therapeutics AG
- Bausch Health Companies Inc.
- Baxter International Inc.
- Galen Ltd.
- GENFIT SA
- Gilead Sciences Inc.
- Innocan Pharma Corp. Ltd.
- Johnson and Johnson Services Inc.
- Leadiant Biosciences Inc.
- Lipella Pharmaceuticals Inc.
- Liposoma B.V.
- Merrimack Pharmaceuticals Inc.
- Nanovex Biotechnologies SL
- Pacira BioSciences Inc.
- Spectrum Pharmaceuticals Inc.
- Taiwan Liposome Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- The Lubrizol Corp.
- Vascular Biosciences
- Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/2sq91b-liposomal?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
